, Volume 8, Issue 2, pp 175–176 | Cite as

Should the Philosophy of Postmarketing Surveillance in the US be Redefined?

  • Javier Soto
  • J. A. Sacristan


Clinical Ethic Scientific Rigour Ethic Consultant Daily Medical Practice Drug Promotion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    La Puma J. Physician rewards for postmarketing surveillance (seeding studies) in the US. PharmacoEconomics 1995; 7 (3): 187–90PubMedCrossRefGoogle Scholar
  2. 2.
    Members ofthe ASCPT Pharmacoepidemiology Section. Notes of the American Society for Clinical Pharmacology and Therapeutics: position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clin Pharmacol Ther 1990; 48: 598CrossRefGoogle Scholar
  3. 3.
    Jefferys DB, Jones KH. EMEA and the new pharmaceutical procedures for Europe. Eur J Clin Pharmacol 1995; 47: 471–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Javier Soto
    • 1
  • J. A. Sacristan
    • 2
  1. 1.Pharmacoepidemiology Unit, Medical DepartmentAbbott Laboratories S.A.MadridSpain
  2. 2.Pharmacoepidemiology and Pharmacoeconomics, Unit, Clinical Research DepartmentLilly S.A.MadridSpain

Personalised recommendations